SAGA dividend history

NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Sagaliam Acquisition Corp. ("SAGAU", "SAGA", SAGAR") (the "Company") announced that Sagaliam entered into a Novation Agreement with Enzolytics, Inc. (OTC:ENZC), Biogenysis, Inc. (BGEN), and Virogentics, Inc. (VIRO) (together the "Parties"). ​Under this restructured agreement SAGA retains 100% ownership of VIRO, ITV-1, the nutraceutical products and license along with VIRO's other assets. This agreement transferred ownership of Biogenysis, Inc. ("BGEN") and it's IP, patents and associated asset being developed back to ENZC in exchange for a reduction of the price from $450,000,000 to $290,000,000 with the dividend of the purchase shares to come dir

Provides Updates on SAGA Transaction and on Virogentics, Inc. and Biogenysis, Inc. ProgressALLEN, TX / ACCESSWIRE / November 20, 2023 / Enzolytics, Inc. (OTC:ENZC) (https://enzolytics.com/"https://enzolytics.com/). Enzolytics, Inc. (the "Company") filed an amended December 31, 2022 OTC Annual Report and its delinquent September 30, 2023 OTC quarterly disclosure. The purpose of the amended OTC Annual Report filed today is to include the audited financial statements for December 31, 2022 and 2021. As part of the recently completed sale of the two operating subsidiaries, Virogenetics, Inc. ("VIRO") and Biogenysis, Inc. ("BGEN"), to Sagaliam Acquisition Corp. (NASDAQ:SAGA)("SAGA") post-closing d